Brief: PharmAbcine Enters Into Research Collaboration Agreement With LegoChem Biosciences
11/01/2021 13:50
Jan 11 (Reuters) - PharmAbcine Inc 208340.KQ :
* PHARMABCINE INC - ENTERED INTO A RESEARCH COLLABORATION
AGREEMENT WITH LEGOCHEM BIOSCIENCES INC.
* PHARMABCINE INC - UNDER AGREEMENT, CO WILL PROVIDE PMC-403
TO
LCB SO LCB CAN CONDUCT A COMBINATION RESEARCH USING PMC-403 AND
LCB'S PROPRIETARY ADC
Source text for Eikon: ID:nPnbsJd5Ma
Further company coverage: 208340.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PharmAbcine
See all newsBrief: Pharmabcine Announces Safety Approval For 1st dose Cohort In Phase 1A/B Clinical Trial Of Pmc-309
Brief: Pharmabcine To Conduct Capital Increase Of 26 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 3.7 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 4.7 Billion Won For Operational Funds
Brief: PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration